Technological Advantages

Exceptional Therapeutic Potential

Low-dose subcutaneous administration of LIB-101 is sufficient to elicit hematologic and immune-mediated therapeutic effects

Excellent Safety Profile

Safety data from more than 200 healthy subjects demonstrate favorable safety and tolerability

Key
Highlight

Backed by the U.S. government, having secured USD 76M in R&D funding for the development of HSARS applications

High Competitive Barrier

The most advanced IL-12 drug in development on the market, with full first-in-class patent protection

Significant Market Potential

Can serve as an adjunct to radiotherapy/chemotherapy and immunotherapy, applicable across multiple indications

Combination with Immunotherapy
In early-stage studies, LIB-101 has demonstrated favorable anti-tumor synergy with immune checkpoint inhibitor therapies and helps improve the overall response rate of immunotherapy.
Combination with Radiotherapy
Across multiple studies, LIB-101 has shown positive effects on bone marrow protection, hematopoietic stem cell regeneration, erythropoiesis, leukopoiesis, and thrombopoiesis. In addition, intervention with LIB-101 helps extend patients' duration of response to therapy.
Combination with Chemotherapy
In studies combining LIB-101 with chemotherapy, the goal is to alleviate the side effects experienced by lymphoma patients during chemotherapy (such as reduced blood cell counts, infectious complications, and fatigue), helping to improve patients' overall Objective Response Rate (ORR) during treatment.
Efficacy and Clinical Usability
LIB-101's subcutaneous formulation effectively extends the drug's duration of action in the body and significantly controls the desensitization or hypersensitivity reactions commonly associated with cytokine therapies. Current clinical trials also support extending the dosing interval for the subcutaneous formulation of LIB-101.
Well-established Clinical Safety Data
To date, LIB-101 has accumulated clinical safety data from more than 200 healthy subjects. Clinical safety data continue to accumulate from combination trials with common cancer therapies, including antibody drugs, chemotherapy agents, immune checkpoint inhibitors, and radiotherapy.
Broad Therapeutic Applications
LIB-101 demonstrates synergistic effects across different aspects of efficacy when combined with today's mainstream cancer therapies, such as antibody drugs, chemotherapy, immune checkpoint inhibitors, and radiotherapy, while also showing a trend toward reducing the side effects of these existing therapies.